219 related articles for article (PubMed ID: 25417058)
21. Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
Uchida A; Myoui A; Araki N; Yoshikawa H; Shinto Y; Ueda T
Cancer; 1997 Jan; 79(2):411-5. PubMed ID: 9010116
[TBL] [Abstract][Full Text] [Related]
22. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
Hawkins DS; Arndt CA
Cancer; 2003 Dec; 98(11):2447-56. PubMed ID: 14635080
[TBL] [Abstract][Full Text] [Related]
23. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen.
Ferrari S; Sassoli V; Orlandi M; Strazzari S; Puggioli C; Battistini A; Bacci G
J Chemother; 1993 Apr; 5(2):135-41. PubMed ID: 8515297
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
Bacci G; Longhi A; Forni C; Fabbri N; Briccoli A; Barbieri E; Mercuri M; Balladelli A; Ferrari S; Picci P
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):505-11. PubMed ID: 17118571
[TBL] [Abstract][Full Text] [Related]
25. [The importance of dose intensity in preoperative chemotherapy for osteosarcoma--retrospective analysis of a short intensive chemotherapy regimen preoperatively using high-dose methotrexate and cisplatinum].
Takahashi M; Katagiri H; Sato K; Sugiura H; Yamamura S; Fukaya N; Nakanishi K
Gan To Kagaku Ryoho; 1994 Mar; 21(4):459-64. PubMed ID: 8129386
[TBL] [Abstract][Full Text] [Related]
26. [Effectiveness and safety of polyethylene glycol liposome doxorubicin in the treatment of osteosarcoma].
Yang YK; Xu HR; Huang Z; Li Y; Niu XH
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):692-696. PubMed ID: 32867464
[No Abstract] [Full Text] [Related]
27. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718
[TBL] [Abstract][Full Text] [Related]
28. [Chemotherapy for osteosarcoma--trends in recent years].
Fujinami S; Nakaseko K; Ogihara Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1908-14. PubMed ID: 8215462
[TBL] [Abstract][Full Text] [Related]
29. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
30. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
[TBL] [Abstract][Full Text] [Related]
31. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy.
Ferrari S; Bacci G; Picci P; Mercuri M; Briccoli A; Pinto D; Gasbarrini A; Tienghi A; Brach del Prever A
Ann Oncol; 1997 Aug; 8(8):765-71. PubMed ID: 9332684
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
34. [Significance of surgical adjuvant chemotherapy in osteosarcoma].
Yamawaki S; Isu K; Ubayama Y; Goto M; Kobayash M; Ishii S; Usui M; Yagi T; Sasaki T
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 2):1430-7. PubMed ID: 3496046
[TBL] [Abstract][Full Text] [Related]
35. The value of high-dose methotrexate-based neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone.
Ham SJ; Hoekstra HJ; van der Graaf WT; Kamps WA; Molenaar WM; Schraffordt Koops H
J Clin Oncol; 1996 Feb; 14(2):490-6. PubMed ID: 8636762
[TBL] [Abstract][Full Text] [Related]
36. The effect of intra-arterial versus intravenous cisplatinum in the neoadjuvant treatment of osteosarcoma of the limbs: the experience at the Rizzoli Institute.
Bacci G; Ferrari S; Forni C; Mercuri M; Picci P; Bertoni F; Capanna R; Manfrini M; Donati D; Brach Del Prever A; Baldini N
Chir Organi Mov; 1996; 81(4):369-82. PubMed ID: 9147928
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic factors for the local recurrence of osteosarcoma in extremities treated with combined therapy].
Zhang Q; Niu XH; Cai YB; Hao L; Ding Y
Zhonghua Wai Ke Za Zhi; 2007 Aug; 45(16):1114-7. PubMed ID: 18005614
[TBL] [Abstract][Full Text] [Related]
38. Is it important to maintain high-dose intensity chemotherapy in the treatment of adults with osteosarcoma?
Kushnir I; Kolander Y; Bickels J; Gortzak Y; Flusser G; Issakov J; Merimsky O
Med Oncol; 2014 May; 31(5):936. PubMed ID: 24719037
[TBL] [Abstract][Full Text] [Related]
39. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma.
Bacci G; Loro L; Longhi A; Bertoni F; Bacchini P; Versari M; Picci P; Serra M
Anticancer Drugs; 2006 Apr; 17(4):411-5. PubMed ID: 16549998
[TBL] [Abstract][Full Text] [Related]
40. Variability in dose intensity of high-dose methotrexate for nonmetastatic osteosarcoma.
Leavey PJ; Mantadakis E; Maale G
Pediatr Hematol Oncol; 2002; 19(7):483-9. PubMed ID: 12217194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
